Patents by Inventor Rainer Schobert

Rainer Schobert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 4,5-diarylimidazole derivatives as HDAC inhibitors
    Patent number: 9868750
    Abstract: The present invention relates to a 4,5-diarylimidazole derivative of formulae (I), (II) or (III): or a pharmaceutically acceptable salt thereof, wherein the 4,5-diarylimidazole derivative has a hydroxamic acid residue at a first aryl ring and a residue R1 at a second aryl ring; and wherein R1 is hydrogen, a halogen atom or an unsubstituted or substituted alkoxy group; R2 is independently selected from an unsubstituted or substituted alkyl, alkoxy or alkene group; M is a metal atom; L is a halogen atom, an unsubstituted or substituted phosphane, sulfane, arene or alkene group or a 4,5-diarylimidazole-derivative of formula (I); and n is an integer of from 1 to 5.
    Type: Grant
    Filed: July 13, 2015
    Date of Patent: January 16, 2018
    Assignees: CHARITÉ—UNIVERSITÄTSMEDIZIN BERLIN, UNIVERSITÄT BAYREUTH
    Inventors: Michael Höpfner, Bernhard Biersack, Rainer Schobert, Katharina Mahal
  • Hydrodabcyl
    Publication number: 20170327460
    Abstract: A new azobenzene-based fluorescence quencher with excellent solubility in aqueous solution is described here. This compound represents an optimized alternative to dabcyl in a variety of biomolecular applications, like fluorogenic protease substrates or nucleic acids probes.
    Type: Application
    Filed: November 27, 2015
    Publication date: November 16, 2017
    Inventors: Elisa BOMBARDA, Oxana KEMPF, Karl KEMPF, Rainer SCHOBERT, G. Matthias ULLMANN
  • Hydrodabcyl
    Patent number: 9815774
    Abstract: A new azobenzene-based fluorescence quencher with excellent solubility in aqueous solution is described here. This compound represents an optimized alternative to dabcyl in a variety of biomolecular applications, like fluorogenic protease substrates or nucleic acids probes.
    Type: Grant
    Filed: November 27, 2015
    Date of Patent: November 14, 2017
    Assignee: UNIVERSITÄT BAYREUTH
    Inventors: Elisa Bombarda, Oxana Kempf, Karl Kempf, Rainer Schobert, G. Matthias Ullmann
  • 4,5-DIARYLIMIDAZOLE DERIVATIVES AS HDAC INHIBITORS
    Publication number: 20170197992
    Abstract: The present invention relates to a 4,5-diarylimidazole derivative of formulae (I), (II) or (III): or a pharmaceutically acceptable salt thereof, wherein the 4,5-diarylimidazole derivative has a hydroxamic acid residue at a first aryl ring and a residue R1 at a second aryl ring; and wherein R1 is hydrogen, a halogen atom or an unsubstituted or substituted alkoxy group; R2 is independently selected from an unsubstituted or substituted alkyl, alkoxy or alkene group; M is a metal atom; L is a halogen atom, an unsubstituted or substituted phosphane, sulfane, arene or alkene group or a 4,5-diarylimidazole-derivative of formula (I); and n is an integer of from 1 to 5.
    Type: Application
    Filed: July 13, 2015
    Publication date: July 13, 2017
    Inventors: Michael Höpfner, Bernhard Biersack, Rainer Schobert, Katharina Mahal
  • Combretastatin analogs for use in the treatment of cancer
    Patent number: 8980933
    Abstract: The present invention relates to specific analogs of combretastatin, in particular the compounds of formula (I) as described and defined herein, and pharmaceutical compositions comprising the compounds, as well as their medical use, in particular in the treatment or prevention of cancer, including multidrug-resistant cancer.
    Type: Grant
    Filed: May 5, 2011
    Date of Patent: March 17, 2015
    Assignees: Universitat Bayreuth, Martin-Luther-Universitat Halle-Wittenberg
    Inventors: Rainer Schobert, Bernhard Biersack, Thomas Müller
  • COMBRETASTATIN ANALOGS FOR USE IN THE TREATMENT OF CANCER
    Publication number: 20130137740
    Abstract: The present invention relates to specific analogs of combretastatin, in particular the compounds of formula (I) as described and defined herein, and pharmaceutical compositions comprising the compounds, as well as their medical use, in particular in the treatment or prevention of cancer, including multidrug-resistant cancer.
    Type: Application
    Filed: May 5, 2011
    Publication date: May 30, 2013
    Inventors: Rainer Schobert, Bernhard Biersack, Thomas Müller